| Date | Title | Description |
| 30.10.2025 | Biodesix CEO rings Nasdaq’s closing bell | Five years to the day after taking Biodesix Inc. (Nasdaq: BDSX) public, president and CEO Scott Hutton celebrated the milestone — and the company regaining compliance with the exchange — by ringing Nasdaq’s closing bell Tuesday.
Already hav... |
| 22.10.2025 | Biodesix announces expanded Bio-Rad Laboratories partnership agreement to develop Droplet Digital™ PCR High Complexity Assays | Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing
LOUISVILLE, Colorado — October 22, 2025 — Biodesix, Inc., a leading diagnostics solutions company, announces the signin... |
| 12.09.2025 | Biodesix stock plummets on news of reverse stock split | Biodesix Inc. (Nasdaq: BDSX), a Louisville-based diagnostic solutions company, saw its stock price dive in early trading Thursday after the company went public with its plans to initiate a one-for-20 reverse stock split next week.
Subscribe... |
| 11.08.2025 | Biodesix reports strong Q2 revenue growth | Biodesix Inc. (Nasdaq: BDSX), a Louisville-based diagnostic solutions company, reported strong revenue growth in the second quarter, but its loss was higher than analyst expectations.
Subscribe to continue reading this article.
Already subs... |
| 08.08.2024 | Business | Biodesix raises sale guidance after strong second quarter | Louisville’s Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung disease, has boosted its revenue expectations for fiscal 2024 on the heels of a strong performance in the second quarter.... |
| 10.05.2024 | Business | Lung disease diagnostics firm Biodesix improved results in Q1 | This article was first published by BizWest, an independent news organization, and is published under a license agreement. © 2024 BizWest Media LLC. You can view the original here: Lung disease diagnostics firm Biodesix improved results in ... |
| 10.05.2024 | Business | Black homeowners start to close gap in property values | Recent research has revealed that homes in majority-Black areas are more likely than those in majority-white areas to be appraised below purchase offers. The disparity remains high but has improved recently, according to federal statistics.... |
| 05.05.2024 | Business | Boulder life-sciences leaders: Pfizer’s exit means opportunity | Lefkoff listed “six identifiable spinoffs” since Pfizer bought Array, four of which are publicly traded companies. They’re all doing very well.
“That’s what you want to see in an ecosystem like ours,” he said. “Nobody leaves, nobody’s freak... |
| 13.07.2023 | Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating | New publication in PLOS ONE, a journal of the Public Library of Science, reaffirms clinical utility of the Nodify XL2® proteomic test in a real-world setting
Biodesix, a leading data-driven diagnostic solutions company with a focus in lung ... |
| 23.11.2022 | Business
Business | Boulder’s Biodesix closes $40M stock offering | Biodesix Inc. (Nasdaq: BDSX), a Boulder life-sciences company that specializes in developing tools to detect lung disease, has closed on an upsized public stock offering that grossed $40.3 million.
The offering, launched last week in order ... |
| 09.03.2021 | Biodesix to Report Fourth Quarter and Fiscal 2020 Financial Results on March 16, 2021 | BOULDER, Colo.--(BUSINESS WIRE)--Mar 9, 2021--
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and... |
| 09.07.2019 | Boulder-based Biodesix announces partnership to develop liquid biopsy | Boulder-based lung cancer diagnostic company Biodesix announced Tuesday that it has entered into an agreement with Thermo Fisher Scientific to bring a blood-based DNA sequencing analysis for liquid biopsies to the general public.
Unlike tra... |
| 30.06.2019 | Biodesix to buy U.S. lab, lung nodule test from Oncimmune | A U.S.-based diagnostics company is expanding its presence in lung cancer with the acquisition of assets from a firm based in the U.K.
Boulder, Colorado-based Biodesix said Friday that it would buy Nottingham, U.K.-based Oncimmune’s U.S. op... |
| 28.06.2019 | Biodesix extends its blood-based lung cancer diagnostic portfolio | Boulder-based Biodesix, Inc. is acquiring a Kansas lab run by Oncimmune Holdings, a global immunodiagnostics group, and is partnering with it to help commercialize its lung nodule malignancy risk test in the United States as part of an agre... |
| 16.04.2019 | Guardant Health study shows liquid biopsy picking up more mutations, delivering faster results | Based on interviews with oncologists, Cannacord analyst Mark Massaro wrote in a note to clients Tuesday that the doctors indicated the NILE study “may usher in a blood-first paradigm” in testing, particularly given the ability to find more ... |
| 09.07.2018 | Biodesix acquires Seattle-based developer of blood-based lung nodule test | Results of the prospective clinical trial PANOPTIC showed that XL2 was 98 percent effective at distinguishing benign from malignant nodules.
In March, Biodesix announced a follow-on sale to increase the size of its offering of Series G shar... |
| 23.06.2015 | Biodesix Raises Additional $11M in Series E Financing | Biodesix Inc., a Buolder, Co.-based molecular diagnostics company that researches, develops and commercializes rapid, blood-based tests for precision medicine in oncology, raised another $11m in Series E financing.
Existing Biodesix shareho... |
| 12.01.2015 | Biodesix Raised Additional $12M in Series E Funding | Biodesix, Inc., a Boulder, Colo.-based molecular diagnostics company that develops and commercializes blood-based tests in oncology enabling physicians to make more precise diagnostic and therapeutic decisions, raised an additional $12m in ... |
| 14.01.2014 | Biodesix Raises Additional $6.1M in Series E Funding | Biodesix, Inc., a Boulder, CO-based molecular diagnostic company dedicated to personalizing medicine, raised an additional $6.1m in Series E funding.
This added to the $8.3m first close of the round announced a month ago (read here) with pr... |
| 02.12.2013 | Biodesix Closes $8.3M Series E Equity Financing | Biodesix, a Boulder, CO-based molecular diagnostic company dedicated to personalizing medicine, closed an $8.3m Series E equity financing.
New funds accounted for $4.3m and the remaining $4m came from the conversion of a convertible note.
E... |
| 12.04.2013 | Biodesix Closes $8.8M Series D Financing | Biodesix, Inc., a Boulder, CO-based molecular diagnostics company advancing the development of innovative products for personalizing medicine, closed on $8.8m in Series D financing.
Backers included unnamed existing shareholders.
Led by CEO... |
| 08.08.2012 | Cancer diagnostics company using genomics analysis raising $1.3 million | Location: Pittsburgh, Pennsylvania.
Solution/product: The biotechnology company uses genomics analysis to detect cancer. PathFinder TG uses molecular analysis of mutations in genomic DNA to provide a more accurate reading in cases where tra... |
| 11.11.2010 | Biodesix Receives $7.1M in Series C Financing Round; $1.4M in Grants | Biodesix Inc., a Broomfield, CO-based personalized medicine company focused on the development of diagnostic products, has raised $7.1m in Series C financing round.
The investment was led by existing backers – which provided $5.1m – with pa... |
| - | Biodesix Announces Fourth Quarter and Full Year 2020 Results | BOULDER, Colo.--(BUSINESS WIRE)--Mar 16, 2021--
Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the fourth quarter and full y... |
| - | Biodesix acquires Seattle-based developer of blood-based lung nodule test | A company specializing in molecular diagnostics and liquid biopsy tests has acquired a firm developing a test designed to determine whether nodules in patients’ lungs are cancerous.
Biodesix, based in Boulder, Colorado, said Monday that it ... |
| - | Biodesix to buy U.S. lab, lung nodule test from Oncimmune | A U.S.-based diagnostics company is expanding its presence in lung cancer with the acquisition of assets from a firm based in the U.K.
Boulder, Colorado-based Biodesix said Friday that it would buy Nottingham, U.K.-based Oncimmune’s U.S. op... |
| - | Guardant Health study shows liquid biopsy picking up more mutations, delivering faster results | Published results of a liquid biopsy study in lung cancer patients could lead oncologists to prioritize blood-based genomic sequencing over traditional tissue testing.
Redwood City, California-based Guardant Health said Monday that it had p... |
| - | Cancer diagnostics company using genomics analysis raising $1.3 million | Company name: RedPath Integrated Pathology.
Industry: Cancer diagnostics.
Location: Pittsburgh, Pennsylvania.
Solution/product: The biotechnology company uses genomics analysis to detect cancer. PathFinder TG uses molecular analysis of muta... |
